Type 2 Diabetes Mellitus
Conditions
Brief summary
Primary Objective: To assess the effect of repeated once-daily oral doses of sotagliflozin on CYP2D6 and CYP3A activities using a CYP probe cocktail of metoprolol and midazolam. Secondary Objective: To assess the clinical and laboratory safety of sotagliflozin coadministered with the cocktail probes as compared to that of cocktail probes alone.
Detailed description
The total study duration per subject is up to 58 days.
Interventions
Pharmaceutical form: tablet Route of administration: oral
DRUGmidazolam
Pharmaceutical form: HCl syrup Route of administration: oral
DRUGmetoprolol
Pharmaceutical form: tablet Route of administration: oral
Sponsors
Sanofi
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
: * Male or female healthy subjects, between 18 and 55 years of age, inclusive. * Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m\^2, inclusive. * Normal vital signs, electrocardiogram (ECG), and laboratory parameters * Female subjects must use a double contraception method during the study, except if she has undergone sterilization at least 3 months earlier or is postmenopausal. The accepted double contraception methods include the use of one of the following contraceptive options: (1) condom; (2) diaphragm or cervical/vault cap; (3) spermicide in addition to the use of one of the following: a) Intrauterine device (IUD); b) Vasectomized partner; c) Sexual abstinence. Hormonal contraception is NOT acceptable in this study.
Exclusion criteria
Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness. Frequent headaches and/or migraine, recurrent nausea and/or vomiting. * Blood donation, any volume, within 2 months before inclusion. * Symptomatic postural hypotension. * Presence or history of drug hypersensitivity, allergic disease or asthma diagnosed and treated by a physician. * History or presence of drug or alcohol abuse. * If female, pregnancy or breast-feeding. * Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Any oral contraceptives during the screening period or for at least 15 days prior to the first dose of Period 1; any injectable contraceptives or hormonal intrauterine devices within 12 months prior to the first dose of Period 1; or topical controlled delivery contraceptives (patch) for 3 months prior to the first dose of Period 1. * Any contra-indications to metoprolol, according to the applicable labeling. * Any contra-indications to midazolam, according to the applicable labeling. * Any consumption of citrus (grapefruit, orange, etc.) or their juices within 5 days before inclusion. * Any history or presence of deep leg vein thrombosis or embolism or a recurrent or frequent appearance of deep leg vein thrombosis in first degree relatives (parents, siblings or children). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of midazolam pharmacokinetic (PK) parameter: Area under the curve (AUC) | Day 1 to Day 2 of Treatment A Period |
| Assessment of midazolam PK parameter: AUC | Day 11 to Day 12 of Treatment B Period |
| Assessment of metoprolol PK parameter: AUC | Day 1 to Day 3 of Treatment A Period |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of PK parameter: Tmax | Day 11 to Day 12 of Treatment B Period (midazolam) |
| Assessment of PK parameter: maximum plasma concentration (Cmax) | Day 1 to Day 2 of Treatment A Period (midazolam) |
| Assessment of PK parameter: t1/2z | Day 11 to Day 12 of Treatment B Period (midazolam) |
| Assessment of PK parameter: terminal-half life (t1/2z) | Day 1 to Day 2 of Treatment A Period (midazolam) |
| Assessment of PK parameter: Cmax | Day 11 to Day 12 of Treatment B Period (midazolam) |
| Assessment of PK parameter: time to reach Cmax (Tmax) | Day 1 to Day 2 of Treatment A Period (midazolam) |
Countries
United States
Outcome results
None listed